JP2024522075A - 抗ｃｅａ及び抗ｃｄ１３７多重特異性抗体ならびにそれらの使用方法 - Google Patents

抗ｃｅａ及び抗ｃｄ１３７多重特異性抗体ならびにそれらの使用方法 Download PDF

Info

Publication number
JP2024522075A
JP2024522075A JP2023571801A JP2023571801A JP2024522075A JP 2024522075 A JP2024522075 A JP 2024522075A JP 2023571801 A JP2023571801 A JP 2023571801A JP 2023571801 A JP2023571801 A JP 2023571801A JP 2024522075 A JP2024522075 A JP 2024522075A
Authority
JP
Japan
Prior art keywords
seq
antigen
antibody
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522075A5 (https=
Inventor
ク、リャン
チャン、トン
リ、ズオ
チェン、シン
ズー、リン
ワン、ペンハオ
ジョウ、シャオスイ
シィエ、ユァンユァン
リ、ジエ
ソン、ジアン
ソン、ジン
リ、シュエフイ
Original Assignee
ベイジーン スウィッツァーランド ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベイジーン スウィッツァーランド ゲーエムベーハー filed Critical ベイジーン スウィッツァーランド ゲーエムベーハー
Publication of JP2024522075A publication Critical patent/JP2024522075A/ja
Publication of JP2024522075A5 publication Critical patent/JP2024522075A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023571801A 2021-05-21 2022-05-18 抗ｃｅａ及び抗ｃｄ１３７多重特異性抗体ならびにそれらの使用方法 Pending JP2024522075A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2021095113 2021-05-21
CNPCT/CN2021/095113 2021-05-21
CN2022085625 2022-04-07
CNPCT/CN2022/085625 2022-04-07
CN2022088172 2022-04-21
CNPCT/CN2022/088172 2022-04-21
PCT/CN2022/093565 WO2022242680A1 (en) 2021-05-21 2022-05-18 Anti-cea and anti-cd137 multispecific antibodies and methods of use

Publications (2)

Publication Number Publication Date
JP2024522075A true JP2024522075A (ja) 2024-06-11
JP2024522075A5 JP2024522075A5 (https=) 2025-05-22

Family

ID=84140249

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571801A Pending JP2024522075A (ja) 2021-05-21 2022-05-18 抗ｃｅａ及び抗ｃｄ１３７多重特異性抗体ならびにそれらの使用方法

Country Status (12)

Country Link
US (1) US20240190989A1 (https=)
EP (1) EP4340805A4 (https=)
JP (1) JP2024522075A (https=)
KR (1) KR20240014058A (https=)
CN (1) CN117396182A (https=)
AU (1) AU2022277479A1 (https=)
CA (1) CA3219672A1 (https=)
CO (1) CO2023017609A2 (https=)
IL (1) IL308660A (https=)
MX (1) MX2023013726A (https=)
TW (1) TW202307003A (https=)
WO (1) WO2022242680A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202434306A (zh) * 2022-11-24 2024-09-01 瑞士商百濟神州瑞士有限責任公司 抗ｃｅａ抗體藥物軛合物及使用方法
CN116814664B (zh) * 2023-08-25 2023-12-12 中国医学科学院肿瘤医院 一种扩展肿瘤识别表位的cea嵌合抗原受体t细胞的制备与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506370A (ja) * 2012-11-20 2016-03-03 サノフイ 抗ｃｅａｃａｍ５抗体およびその使用
JP2020504622A (ja) * 2017-01-03 2020-02-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗４−１ｂｂクローン２０ｈ４．９を含む二重特異性抗原結合分子

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3224275B1 (en) * 2014-11-14 2020-03-04 F.Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer
EP3267969A1 (en) * 2015-03-09 2018-01-17 King's College London Combination therapy with rar alpha agonists for enhancing th1 response
CN105753978B (zh) * 2016-03-14 2020-02-07 中国人民解放军第二军医大学 一种hla-a11限制性癌胚抗原来源的表位肽及用途
TWI841551B (zh) * 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
KR20220025848A (ko) * 2019-06-26 2022-03-03 에프. 호프만-라 로슈 아게 Cea 및 4-1bbl에 결합하는 항체의 융합

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506370A (ja) * 2012-11-20 2016-03-03 サノフイ 抗ｃｅａｃａｍ５抗体およびその使用
JP2020504622A (ja) * 2017-01-03 2020-02-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗４−１ｂｂクローン２０ｈ４．９を含む二重特異性抗原結合分子

Also Published As

Publication number Publication date
AU2022277479A1 (en) 2024-01-18
CN117396182A (zh) 2024-01-12
IL308660A (en) 2024-01-01
WO2022242680A1 (en) 2022-11-24
EP4340805A1 (en) 2024-03-27
CO2023017609A2 (es) 2024-01-15
US20240190989A1 (en) 2024-06-13
EP4340805A4 (en) 2026-01-14
CA3219672A1 (en) 2022-11-24
KR20240014058A (ko) 2024-01-31
MX2023013726A (es) 2024-02-13
TW202307003A (zh) 2023-02-16

Similar Documents

Publication Publication Date Title
JP7757247B2 (ja) ヒト化またはキメラｃｄ３抗体
US9884921B2 (en) Bispecific heterodimeric diabodies and uses thereof
CA2957491A1 (en) Neutralization of inhibitory pathways in lymphocytes
US20240209106A1 (en) Anti-cd137 antibodies and methods of use
US20240190989A1 (en) Anti-cea and anti-cd137 multispecific antibodies and methods of use
JP2025524386A (ja) 抗ｃｌｄｎ１８．２抗体を含む二重特異性抗体、並びにその医薬組成物及び使用
US20240190990A1 (en) Anti-cea antibodies and methods of use
US20240124607A1 (en) Proteins binding nkg2d, cd16, and ceacam5
CN114641500B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
US20240209113A1 (en) Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
CN114729051A (zh) 使用抗ox40抗体与放射组合治疗癌症的方法
WO2024109678A1 (en) Anti-cd137 antibodies and methods of use
HK40107933A (zh) 抗gpc3和抗cd137多特异性抗体及使用方法
HK40109079A (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
JP2023534726A (ja) 多発性骨髄腫の治療に使用するための抗ｄｒ５抗体と免疫調節イミド薬との併用
HK40074321B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250107

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303